In this episode of a16z bio Journal Club, general partner Vijay Pande, bio deal team partner Andy Tran, and bio editor Lauren Richardson discuss a novel CRISPR-Cas-based anti-viral strategy.
The discussion covers the differences between this newly developed prophylactic strategy, traditional vaccines, and anti-viral drugs; how this strategy can be engineered to target a huge range of coronavirus and influenza strains; and the next steps needed to go from paper to practice:
a16z Journal Club (part of the a16z Podcast), curates and covers recent advances from the scientific literature -- what papers weβre reading, and why they matter from our perspective at the intersection of biology & technology (for bio journal club). You can find all these episodes at a16z.com/journalclub.
π 2020-05-07 22:00 / β 00:20:32
π 2020-05-06 22:54 / β 00:28:40
π 2020-05-02 03:18 / β 00:13:18
π 2020-04-29 22:00 / β 00:20:36
π 2020-04-26 18:55 / β 00:24:22